Metformin anticancer: Reverses tumor hypoxia induced by bevacizumab and reduces the expression of cancer stem cell markers CD44/CD117 in human ovarian cancer SKOV3 cells

Metformin anticancer: Reverses tumor hypoxia induced by bevacizumab and reduces the expression of cancer stem cell markers CD44/CD117 in human ovarian cancer SKOV3 cells

Background: The occurrence and development of solid tumors depend on the blood supply in the tumor microenvironment (TME). Blocking angiogenesis is a new therapeutic strategy to inhibit tumor growth. The anti-angiogenic drug bevacizumab has been approved for gynecological malignancies, especially fo...

Full description

Bibliographic Details
Main Authors: Yuanchun Fan, Huimin Cheng, Yueping Liu, Shihao Liu, Scott Lowe, Yaru Li, Rachel Bentley, Bethany King, John Pocholo W. Tuason, Qin Zhou, Chenyu Sun, Hui Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Pharmacology
Subjects:
metformin
bevacizumab
CSCs
VEGF
HIF-1α
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.955984/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.955984/full

Similar Items